Board of Directors
Chairman of the Board of Directors, Co-founder, Member of the Nomination and Compensation Committee, Chairman of the Alliances Committee
Jean-François Mouney co-founded GENFIT in 1999 after having been actively involved in the incubation of the Company from 1997. Prior to this, he had created, managed and developed several companies specializing in high-performance materials, particularly in the aeronautical industry, since 1979. In 1992, he founded M&M, a consultancy firm specializing in health economics. He was responsible for carrying out a feasibility study for an economic development agency within the field of health and biology in the Nord-Pas-de-Calais region of France and was appointed Chief Executive Officer of this agency since its launch in 1995. Over a hundred companies have been created as part of this venture, making Eurasanté one of the top European bioincubators and clusters. As Chairman of the Executive Board of GENFIT, he received, in 2003, the Entrepreneur of the Year award, which is organized internationally by Ernst & Young, in the New Technology category. He also received this award in 2004. Jean-François Mouney is also Deputy Chairman of the “Nutrition, Health and Longevity” research hub and is Advisor to the Banque de France since 2008. Jean-François Mouney is a graduate of the ESCP-Europe Business School, and holds a Master Degree in Economics from the University of Lille. Jean-François Mouney was GENFIT’s CEO for 20 years. He took on listing the company on the Nasdaq and lead GENFIT’s transformation from an innovative start-up to a biopharmaceutical company.
Vice-Chairman of the Board of Directors, Chairman of the Nomination and Compensation Committee, Member of the Audit Committee, Member of the Alliances Committee
Graduated from the ESSCA (Ecole Supérieure des Sciences Commerciales d’Angers), from the Institute of Foreign Commerce and from the Management Control Institute, Xavier Guille des Buttes has spent his entire career in the pharmaceutical industry. He has held a large number of executive positions for more than 30 years, particularly in the French subsidiary of the German Group Schering AG, and most recently Chairman of the Management Board until June 2006. Member of GENFIT’s Supervisory Board since 2006, he was chairman from 2008 until he was appointed Vice-Chairman of the Board of Directors of GENFIT following a change in the mode of administration on June 16, 2017. In addition to his responsibilities at GENFIT, he also serves as director of several companies. He holds offices with Atlanta (a start-up based in Nantes), Delpharm Holding (pharmaceutical manufacturing), Hemarina, a start-up located in Morlaix and Medsenic (start-up based in Strasbourg). Xavier Guille Des Buttes also chairs the Foundation of the Catholic University of Lille and is a knight of the Legion of Honor.
Member of the Nomination and Compensation Committee
Since 2012, Dr. Catherine Larue has been CEO of the Integrated Biobank of Luxembourg (IBBL), where she leads the development of the biobanking strategy and new initiatives in the field of personalized medicine. During that time she acted for two years as CEO ad interim of the Luxembourg Institute of Health (LIH), the Luxembourg Biomedical Research Institute. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at GENFIT until 2012. Dr. Catherine Larue began her career as an R&D team leader at Sanofi in the cardiovascular research department. She later joined Sanofi Diagnostics Pasteur in particular as Director, and then spent 11 years at the Bio-Rad group, holding different management positions. She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John’s University (New York).
Chairman of the Audit Committee
Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels. In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. She has extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013.
Member of the Alliances Committee
Frédéric Desdouits is Managing Director of the Company Uetikon (Larh, Germany), part of the Novacap Group (Ecully, France). Prior to joining Novacap in October 2017, Frédéric Desdouits was head of Pierre Fabre Group Business Development, Acquisition and Market Intelligence since 2011. He is also member of the Pharmaceuticals Executive Board and of the Development Products Board. Prior to joining Pierre Fabre, Frederic was Managing Partner at Bionest Partners and the founding Managing Partner of Bionest Partners Finance, a consulting and transaction firm based in Paris and New York specialized in healthcare and biotechnologyand value strategy for emerging bio-companies. Before continuing in finance at Exane BNP Paribas, Frédéric worked in research in several large pharmaceutical groups including GlaxoWellcome in France (now GSK) and Hoechst. Frédéric Desdouits is a member of the Supervisory Board of CiToxLab. Between 2015 and 2017, he also was board observer on the Board of Directors of Orphelia Pharma. Frédéric Desdouits graduated from École Polytechnique (Palaiseau, France), obtained a MS in pharmacology and a PhD in Neurosciences at University Paris VI and Collège de France, did a post-doc (1994-1996) at the Rockefeller University in New York. He is a CEFA (Certified European Financial Analyst) and Certified in Global Management from INSEAD.
Florence Séjourné is the chief executive officer of Da Volterra, a French biotech company that develops innovative products for the prevention and treatment of multi-resistant and life-threatening infections for which the medical need is increasing. Prior to joining Da Volterra in 2008, Florence co-founded GENFIT with Jean-François Mouney and Bart Staels, and spent 11 years as a member of the Executive Board, and in particular held the position of Chief Operating Officer. She has been a member of the Supervisory Board and now Board of Directors of GENFIT since 2008, representing Biotech Avenir, the holding company of GENFIT managers and executives. Furthermore, Florence has been active in contributing to various groups in Europe and in the United States focused on defining creative business models and incentives to face the economic issues of innovation in bacterial infections. She founded and is President of the BEAM Alliance, which represents 35 European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance. In addition, she is a board member, representative of SMEs, in the IRT BioAster, and member of the expert advisory board of GAMRIF, the Global AMR Innovation Fund launched by the UK government. Florence holds a degree in biotechnology from MINES Paritech, in Paris, France and also holds a Master of Science in Pharmaceutical Sciences & Bioengineering from the University of Illinois, Chicago.
Member of the Audit Committee
Graduated from the Institut Catholique des Arts et Métiers de Lille and from the Ecole des Hautes Etudes Commerciales du Nord (EDHEC), Philippe Moons began his career as a business engineer in a French industrial Group. In 1995, he joined Finorpa, a venture capital and growth capital company, operating under the aegis of the Group “Charbonnage de France” and of the Nord-Pas-de-Calais region. Since 2006, he is in charge of supporting and financing several companies in their early-stage activities or development phases; in particular in the fields of biology and health. In addition to his current responsibilities at Finorpa and GENFIT, where he serves as a corporate director, Philippe Moons is a member of the Supervisory Board of Finovam, a regional venture capital company, established in 2014 to strengthen the emergence and provide seed capital to innovative businesses, primarily technological projects in the Nord-Pas-de-Calais region.
Ms. Kalin is currently a director on the boards of Clinical Genomics, a molecular diagnostic firm, Brown Advisory, a strategic advisory and investment firm, and Primari Analytics, a startup in artificial intelligence. From 2012-17, Ms. Kalin led corporate strategy at Celgene, a global biopharmaceutical company, for 5 1/2 years. Prior to that, Ms. Kalin held executive leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson (J&J) from 2002 to 2011. Prior to J&J, Ms. Kalin served as a Partner at McKinsey and Company, a global management consulting firm, where she negotiated and led consulting assignments, as a strategic advisor to pharmaceutical, medical device and other healthcare companies
Mr. Eric Baclet has over 30 years of experience with Eli Lilly in international drug development, management, and commercialization, all expertise he gained as President and General Manager of Lilly Italia, General Manager of Lilly China, VP of Global Marketing, and Executive Directorship of International Marketing, to name a few. Throughout his tenure at Eli Lilly, Mr. Baclet spearheaded international drug launches across multiple geographies, and led multi-disciplinary teams involved in biopharmaceutical value-chain management in more than seven countries.